Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

Sanofi-Aventis to Develop Metabolex’ Type 2 Diabetes Therapy as Part of $375M Deal

Dual-mechanism oral small molecule MBX-2982 acts as GPR119 agonist.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »